Accuray (ARAY)
(Delayed Data from NSDQ)
$2.03 USD
+0.11 (5.73%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $1.97 -0.06 (-2.96%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.03 USD
+0.11 (5.73%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $1.97 -0.06 (-2.96%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Zacks News
Accuray (ARAY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Accuray (ARAY) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Accuray (ARAY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of 0% and 3.51%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Treace Medical Concepts (TMCI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 7.41% and 3.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Accuray Stock in Your Portfolio Now
by Zacks Equity Research
ARAY's solid product demand and revenue growth raise optimism about the stock.
Here's Why You Should Retain Accuray Stock in Your Portfolio Now
by Zacks Equity Research
ARAY's solid product demand and revenue growth raise optimism about the stock.
ARAY Stock Up Following the Use of SGRT on Cancer Patients in Japan
by Zacks Equity Research
The latest adoption of Accuray's Radixact System and VitalHold package is likely to improve the care provided to cancer patients and their experience.
Accuray Stock Rises After Helix System Wins CE Mark for Cancer Care
by Zacks Equity Research
ARAY's Helix system, now CE Mark approved, aims to close global cancer care gaps with cost-effective, high-throughput radiotherapy for underserved regions.
Accuray's (ARAY) Radixact for Cancer Treatment Debuts in US
by Zacks Equity Research
Accuray's (ARAY) Radixact System with VitalHold technology is set to enhance precision and comfort in radiation therapy.
Accuray (ARAY) Q4 Earnings Lag Estimates, Gross Margin Shrinks
by Zacks Equity Research
Despite improving product sales, Accuray (ARAY) reports mixed fourth-quarter fiscal 2024 results.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Accuray's (ARAY) solid product demand raises optimism about the stock.
Accuray (ARAY), TrueNorth Unite to Aid Radiation Departments
by Zacks Equity Research
Accuray (ARAY) announces an agreement with TrueNorth to provide radiation oncology departments with third-party support designed to improve their department's capabilities.
Accuray's (ARAY) Precision TPS Gets Approved by China's NMPA
by Zacks Equity Research
Accuray (ARAY) announces the approval of the Accuray Precision Treatment Planning System by the Chinese Medical Products Administration.
Inogen (INGN) Down 0.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Accuray (ARAY) Up 2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for May 31st
by Zacks Equity Research
ASGN, ARAY and BGS have been added to the Zacks Rank #5 (Strong Sell) List on May 31, 2023.
New Strong Sell Stocks for May 24th
by Zacks Equity Research
DDD, ARAY and BNTGY have been added to the Zacks Rank #5 (Strong Sell) List on May 24, 2023.
Accuray (ARAY) Q3 Earnings Lag Estimates, Gross Margin Contracts
by Zacks Equity Research
Despite strength in radiation oncology, Accuray (ARAY) reports dismal third-quarter fiscal 2024 results.
Accuray (ARAY) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of -500% and 11.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for These 4 Medical Device Stocks in Q1 Earnings?
by Indrajit Bandyopadhyay
Here is a sneak peek into how the four medical device stocks, COR, GKOS, ARAY and SRDX, might fare in their quarterly results slated to be release tomorrow.
Inari Medical, Inc. (NARI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inari Medical (NARI) delivered earnings and revenue surprises of -136.36% and 3.53%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Can the 4 Medical Device Stocks Hit Targets This Earnings Season?
by Debanjana Dey
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, GKOS, SRDX and ARAY are placed ahead of their earnings releases.
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
by Zacks Equity Research
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.
Accuray's (ARAY) CyberKnife Improves Prostate Cancer Treatment
by Zacks Equity Research
Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Accuray's (ARAY) solid product demand raises optimism about the stock.
Accuray (ARAY) Up 1.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.